Speaker illustration

Doctor G Kees Hovingh

AMC Medical Research BV, Amsterdam (Netherlands (The))

Efficacy of evinacumab in homozygous familial hypercholesterolemia patients with null or non-null LDL-receptor mutations and on various background therapies

Event: ESC CONGRESS 2017

Topic: Drug therapy

Session: Optimising cardiovascular pharmacotherapy

Thumbnail

PCSK9 inhibition across a wide spectrum of patients: for whom is it efficacious?

Event: ESC CONGRESS 2017

Topic: Lipids (Epidemiology and Prevention)

Session: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies (EBAC Accredited)

Thumbnail

Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolaemia

Event: ESC CONGRESS 2016

Topic: Primary cardiovascular prevention: interventions and outcomes

Session: Cardiovascular prevention outcomes I

Thumbnail

This platform is supported by

logo Novo Nordisk